GT Medical Technologies, Inc. announced today that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA. The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy.
A diagnosis of cancer is shocking for most people. But a diagnosis of brain cancer may carry additional fear when one considers these facts: no other cancer is as challenging to effectively treat as brain cancer, and the average five-year survival rate for people with malignant brain tumors is about 36%.
Fortunately, the availability of a novel treatment called GammaTile® Therapy is offering hope for people like 68-year-old Jane Finch Hall.
Saint Alphonsus doctors are now the first in the Northwest to use GammaTile–a radiation therapy treatment for brain tumors.
The FDA-cleared treatment surgically implants postage-stamp-sized tiles which provide radiation over the course of 33 days and then disintegrate.
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor.
Mayfield Brain & Spine’s Vincent DiNapoli, M.D., Ph.D. was the first surgeon in the eastern U.S. to perform surgery on recurrent brain tumors using a new radiation delivery technique called GammaTile Therapy. Now, he’s partnered with Oncology Hematology Care and Jewish Hospital – Mercy Health (where he’s also the director of the Brain Tumor Center) for a new study using GammaTile to treat newly diagnosed primary cancer that’s moved to the brain. DiNapoli explains how the treatment works.
Precision medicine is revolutionizing cancer treatment. Instead of using the same treatment for the same type of cancer, precision medicine tailors treatment to each individual. Precision medicine—also known as personalized medicine—takes into account someone’s genes, lifestyle and environment to find the most effective course of action for them.
Surgeons at Henry Ford Health System have treated a patient with a recurrent brain tumor by delivering a dose of radiation directly to the cancer inside the brain, a novel approach that could delay or prevent future tumor cells from regrowing.
For the first time in North Florida, a unique new radiation therapy for brain cancer patients was used at Orange Park Medical Center in June.
Endovascular neurosurgeon Michael Horowitz performed the GammaTile Therapy, inserting tiny collagen “tiles” into the brain to delay regrowth after a cancerous tumor was removed, according to the hospital.
Patients with some types of cancerous brain tumors require radiation treatment after they have the tumor removed, to destroy any remaining cancer cells.
Neurosurgeon Harish Babu, MD, PhD, is co-director of Upstate’s brain tumor program and director of minimally invasive neurosurgery.
Now there’s the option to have the tumor removed and replaced by postage stamp-sized radiation sources, in the same operation. It’s called GammaTile Therapy.
Imagining a future with new life-saving approaches for brain cancer may soon become reality. “I think the holy grail is some kind of treatment that cures a person from a biologic level. If we could cure without radiation at all that would be ideal,” Mohiuddin says. For the thousands of people diagnosed with brain cancer every year, this future can’t come soon enough. Until then, the addition of new tools such as GammaTile offer some hope for living with brain cancer.